Overview
- A Tuesday announcement between Novo Nordisk and OpenAI set a strategic deal to deploy AI across research, manufacturing, and commercial teams, with pilots starting now.
- Novo said it will use OpenAI’s models to sift huge biomedical datasets, spot promising drug candidates earlier, and cut the time from lab work to patient access.
- OpenAI will train Novo’s global workforce to use the tools, and CEO Mike Doustdar said the goal is to “supercharge” scientists rather than replace them.
- The company targets full integration by the end of 2026 and stressed strong data protection, formal governance, and human oversight for all use cases.
- Novo did not disclose financial terms, and shares rose about 2.8% after the open as the company works to regain ground on Eli Lilly in the fast-growing obesity drug market.